Docetaxel micellar

ApprovedSmall molecule

Docetaxel micellar is one of 185 small molecule programs targeting Nasopharyngeal Carcinoma. It is currently in Approved.

Indications

Total Trials

Active Trials

184

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nasopharyngeal CarcinomaActive, not recruiting

Lung CancerActive, not recruiting

Esophageal CancerActive, not recruiting

Pharynx CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Gastric CancerActive, not recruiting

Small Cell Lung CancerActive, not recruiting

Nasopharyngeal CarcinomaPhase 2

Active, not recruiting

Lung CancerPhase 2

Active, not recruiting

Esophageal CancerPhase 2

Active, not recruiting

Pharynx CancerPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Ovarian CancerPhase 2

Active, not recruiting

Gastric CancerPhase 3

Active, not recruiting

Small Cell Lung CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Docetaxel micellar

Sanofi

Approved

2 2

Lenvima

Eisai

Preclinical

6 3

Imjudo

AstraZeneca

Preclinical

5 4

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 5

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 6

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 7

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—8

Huaier Granule

QQidong Gaitianli Medicines Co., Ltd

Preclinical

3 9

Immune Checkpoint Inhibitor

IImmuneSensor Therapeutics Inc.

Preclinical

3 10

Immune Checkpoint Inhibitors

PPeking Union Medical College Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Not yet recruiting

Neoadjuvant Therapy

NCT07371897

Clinical

Trials by Indication[1]

Esophageal Cancer2 trials

Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Cannot Be Removed By Surgery

Completed·SSwiss Cancer Institute·Phase 2·NCT00238407·21 enrolled

Involved Field Irradiation (IFI) Versus Elective Nodal Irradiation (ENI) for Esophageal Cancer

Completed·CChengya Chou·N/A·NCT01551589·220 enrolled

Non-Small Cell Lung Cancer2 trials

Biweekly Schedule of Docetaxel and Cisplatin in High Risk Patients With Unresectable Non-small Cell Lung Cancer (NSCLC)

Completed·GGyeongsang National University Hospital·Phase 2·NCT00995761·48 enrolled

The Synergistic Metastases Annihilation With Radiotherapy and Docetaxel (Taxotere) [SMART] Trial for Non-Small Cell Lung Cancer (NSCLC)

Terminated·UUniversity of Chicago·Phase 2·NCT00887315·11 enrolled

Nasopharyngeal Carcinoma2 trials

GP VS TP in the Treatment of Advanced Nasopharyngeal Carcinoma in Northwest China

Completed·—·Phase 2·NCT01596868·60 enrolled

Clinical Target Volume Based on Disease Extension Risk Atlas and Computer-aided Delineation in Nasopharyngeal Carcinoma

Unknown status·SSun Yat-sen University·N/A·NCT02627807·386 enrolled

Gastric Cancer1 trial

FOLFIRI Versus Docetaxel and Cisplatin as a Second-line Chemotherapy After Failure of First-line Chemotherapy in Advanced Gastric Cancer

Completed·YYonsei University·Phase 3·NCT03067792·52 enrolled

Small Cell Lung Cancer1 trial

Adjuvant Cisplatin and Docetaxel in Non Small Cell Lung Cancer

Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT00582634·4 enrolled

9 more indications

Advanced Head and Neck Cancer1 trial

Study of Combination Docetaxel and Radiotherapy With or Without Cisplatin to Treat Local Advanced Head and Neck Cancer

Completed· Sanofi logo

Sanofi·Phase 2·NCT00521521·86 enrolled

Chemoradiotherapy1 trial

Efficacy of Chemoradiotherapy After Neoadjuvant Cisplatin and Docetaxel in the Nasopharynx Carcinoma

Completed· Sanofi logo

Sanofi·Phase 4·NCT00772681·57 enrolled

Concurrent Chemoradiotherapy1 trial

Safety Study of Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in NSCLC Patients

Terminated· Sanofi logo

Sanofi·Phase 2·NCT00271323·14 enrolled

Ovarian Cancer1 trial

Efficacy and Safety of Subsequent Cisplatin and Docetaxel in Ovarian Cancer

Completed· Sanofi logo

Sanofi·Phase 2·NCT00772863·37 enrolled

Neoadjuvant Therapy1 trial

Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial

Not yet recruiting·SSun Yat-sen University·Phase 3·NCT07371897·154 enrolled

Injury1 trial

Clarify of Predictive Risk Factors of Chemotherapy-induced Liver Injury

Unknown status·SSecond Affiliated Hospital of Nanchang University·Phase 4·NCT03069820·120 enrolled

Pharynx Cancer1 trial

Safety and Efficacy Study of Nimotuzumab Plus Neoadjuvant and Concurrent Chemoradiotherapy to Treat Oropharynx and Hypopharynx Cancer

Unknown status·TThe Second People's Hospital of Sichuan·Phase 2·NCT01516996·80 enrolled

Lung Cancer1 trial

Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer

Completed·SSun Yat-sen University·Phase 2·NCT02577341·122 enrolled

Phase 11 trial

Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC

Terminated·SSwiss Cancer Institute·Phase 1·NCT04629781·11 enrolled

Sources

References

[1]
ClinicalTrials.gov — 17 trial records for Docetaxel micellar. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Docetaxel micellar compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Docetaxel micellar. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Sanofi

Docetaxel micellar

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Esophageal Cancer2 trials

Non-Small Cell Lung Cancer2 trials

Nasopharyngeal Carcinoma2 trials

Gastric Cancer1 trial

Small Cell Lung Cancer1 trial

Advanced Head and Neck Cancer1 trial

Chemoradiotherapy1 trial

Concurrent Chemoradiotherapy1 trial

Ovarian Cancer1 trial

Neoadjuvant Therapy1 trial

Injury1 trial

Pharynx Cancer1 trial

Lung Cancer1 trial

Phase 11 trial

References

Drug Info

Quick Facts

Related News